HSV-1减毒活疫苗VC2在豚鼠模型中对HSV-2生殖道感染的保护作用
研究在豚鼠生殖器疱疹模型中评估了HSV-1减毒活疫苗VC2的致病性、预防性和治疗性效果。VC2经阴道接种后毒力显著减弱,不引起生殖道疾病且极少感染神经组织;预防性接种可降低急性和复发性HSV-2疾病的临床严重程度及排毒量,并减少DRG中的病毒量,效果略优于gD2+MPL/Alum疫苗,但无治疗性效果。
要点
- VC2经阴道接种后毒力显著减弱,不引起生殖道疾病且极少感染神经组织。
- 预防性VC2接种降低急性和复发性HSV-2疾病的临床严重程度及排毒量。
- VC2无治疗性疫苗效果。
核心结论
- HSV-1减毒活疫苗VC2在豚鼠生殖器HSV-2模型中具有预防性保护效果,且其感染神经组织能力降低优于其他减毒活疫苗。
研究设计与样本
- 研究在豚鼠生殖器HSV-2模型中评估VC2的致病性,并比较其作为预防性和治疗性疫苗与gD2+MPL/Alum疫苗的保护效果。
主要发现
- VC2在豚鼠中较野生型17syn+显著减毒,接种部位复制差,不产生生殖道疾病,极少感染神经组织。
- 预防性VC2接种降低急性和复发性HSV-2疾病的临床严重程度和排毒量,并减少DRG中的病毒量。
- 与gD2+MPL/Alum相比,VC2效果略优,尤其在神经组织感染方面。
- VC2作为治疗性疫苗无效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although development of an HSV vaccine is a priority there is currently no vaccine available. The recent failure of subunit vaccines suggest that presentation of more antigens via a live attenuated vaccine may be required for protection. We therefore evaluated VC2, a live attenuated HSV vaccine, engineered to be unable to enter into neuronal axons. METHODS: VC2 pathogenesis was first evaluated in guinea pigs following intravaginal inoculation. VC2 was then evaluated as a prophylactic and therapeutic vaccine and compared protection to a gD2 vaccine adjuvanted with MPL/Alum in the guinea pig model of genital HSV-2. The guinea pig model allows evaluation of acute and recurrent disease, as well as vaginal shedding acutely and during episodes of recurrent activation. RESULTS: VC2 was significantly attenuated in guinea pigs compared to the wild type strain, 17syn+. It replicated poorly at the inoculation site, did not produce any genital disease and rarely infected the neural tissue. After prophylactic vaccination, the VC2 vaccine decreased the clinical severity of acute and recurrent HSV-2 disease and shedding and decreased the quantity of virus in the DRGs. When compared to gD2+MPL/Alum, VC2 was somewhat more effective especially as it relates to neural tissue infection. VC2 was not effective as a therapeutic vaccine. CONCLUSION: The live attenuated prophylactic HSV vaccine, VC2, was effective in the guinea pig model of genital HSV-2. Its decreased ability to infect neural tissues provides advantages over other live attenuated vaccines.
引用
- Bernstein DI, Pullum DA, Cardin RD, et al. The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes. Vaccine. 2018. PMID: 30471955. doi:10.1016/j.vaccine.2018.11.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。